ClinicalTrials.gg
Status unknownNCT02784327Updated May 27, 2016

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of PRF110 in Bunionectomy Surgery

A Phase 2 interventional study of PRF110 in Post Operative Pain, sponsored by PainReform LTD. Status unknown at 2 sites in Israel. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2016-05-27.

Sponsored by PainReform LTD · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2016), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies in Pain, Postoperative with a site in Israel — 2 open to participants now, 4 under way, 1 of them phase 3. Pain, Postoperative · Israel.

Planned enrollment
35th of 36
15 · median 99
Started
2016
the only one that year
Phase 2
2 of 41
none open now
Registered
23rd of 41
by date
Lead sponsor
2 of 41
PainReform LTD

Among the 41 studies in Pain, Postoperative with a site in Israel, this one is the 35th largest by planned enrollment of the 36 interventional ones that give a count, is the only one that started in 2016, is one of 2 in phase 2, and was the 23rd registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

2 of the 41 studies in Pain, Postoperative with a site in Israel are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Pain, Postoperative with a site in Israel, or all of them as a file.
02

Study summary

PRF110 is new extended release oily solution formulation of ropivacaine that is intended for local infiltration into surgical wounds. The purpose of this study is to determine the safety and early efficacy of PRF110 in bunionectomy surgery, to measure the pharmacokinetic profile of PRF110 over 72 hours and evaluate the duration of analgesia witnessed in the surgical setting.

Read the detailed description

PRF110 is new extended release oily solution formulation of ropivacaine that is intended for local infiltration into surgical wounds. The formulation is designed to slowly release the ropivacaine over 36-72 hours. By providing local analgesia over a long time span, the need for systemic analgesics is expected to be reduced. The purpose of this study is to determine the safety and early efficacy of PRF110 in bunionectomy surgery, to measure the pharmacokinetic profile of PRF110 over 72 hours and evaluate the duration of analgesia witnessed in the surgical setting.

03

Conditions studied

  • Post Operative Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide written prior to any study procedures;
  2. Able to communicate clearly with the Investigators and study staff;
  3. Males and females aged between 18 - 85 years of age;
  4. Scheduled for elective primary unilateral first metatarsal bunionectomy surgery (osteotomy and internal fixation) with no collateral procedures;
  5. Females must be physically incapable of ( for more than at least 2 years or surgically sterile) or practicing an acceptable method of (hormonal, barrier with spermicide, intrauterine device, vasectomized partner, or abstinence). Subjects using hormonal birth control must have received at least 1 cycle of treatment prior to study drug administration. At Baseline, all females of childbearing potential must have a negative pregnancy test and not be breast feeding;
  6. Negative urine drug screen for drugs of abuse at Screening and on Day 1 prior to surgery; a positive drug screen result may be permitted if the subject has been on a stable dose of an allowed medication for >30 days (antipsychotics, antiepileptics, sedatives, hypnotics, antianxiety agents, or antidepressants);
  7. (ASA) risk class of I to II;
  8. ≤32.

Exclusion criteria

Exclusion Criteria:

  1. Has known allergies to an opioid, unless has subsequently tolerated other opioids and, in the opinion of the Investigator, could tolerate a rescue drug containing fentanyl;
  2. Has a known or suspected allergy to paracetamol, ibuprofen or dipyrone;
  3. Has a known or suspected allergy to any local anesthetic;
  4. Has atrial fibrillation/flutter, an inserted pacemaker, or complete left bundle branch block (LBBB) on ; or myocardial infarction within 6 months prior to surgery;
  5. Has a abnormal ECG at screening;
  6. Has a known or suspected history of diagnosed alcohol, opiate or other substance abuse within 12 months prior to screening;
  7. Is unable to refrain from alcohol consumption for a period beginning 24 hours prior to surgery through the end of the 72 hour evaluation period;
  8. Has taken any analgesic within 12 hours or any aspirin-containing product within 7 days of the Baseline assessments;
  9. Has taken any opioid analgesics or used systemic within 4 days of surgery;
  10. Has been using opiates or any non-steroidal anti-inflammatory drug chronically (more than 10 consecutive days) anytime over the past 3 months;
  11. Has used antipsychotics, antiepileptics, sedatives, hypnotics, antianxiety agents or antidepressants for \< 30 days prior to surgery or had a dose change within the previous 30 days;
  12. Has taken any prescription or over-the-counter medication within 4 days prior to surgery that, in the opinion of the Investigator, could potentially confound the analgesic response;
  13. Has taken herbal agents or nutraceuticals during any of the 7 days prior to surgery that, in the opinion of the Investigator, could potentially confound the analgesic response;
  14. Has any clinically significant condition or a significant laboratory abnormality that would, in the opinion of the Investigator, preclude study participation;
  15. Unable or unwilling, in the opinion of the Investigator to comply with the requirements of the protocol;
  16. Has received another drug within 30 days of scheduled surgery;
  17. Has donated blood within three months prior to start of the study;
  18. Employees of the Investigator and study site or the sponsor, as well as family members of the employees or the investigator or the sponsor.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    PRF110- oily solution

    Post-operative application of new extended release PRF110- oily solution (Ropivacaine)

    Drug: PRF110

Interventions

  • DrugPRF110

    Also known as: Ropivacaine oily solution

06

What researchers measure

Primary outcomes

  1. Incidence of treatment emergent adverse events

    All adverse events (AE) reported by the subjects will be recorded throughout the trial period

    Time frame: 10 days

Secondary outcomes

  1. Time to first rescue medication

    Time to first rescue medication

    Time frame: 72 hours

  2. Total amount of rescue medication used during the study

    Total amount of rescue medication used during the study

    Time frame: 10 days

  3. Pain intensity recorded at rest

    Pain intensity which will be recorded at rest at Hours 1, 2, 4, 6, 8, 10, 12, 18 (optional) 24, 28, 32, 36, 48, 52, 56, 60 and 72.

    Time frame: 72 hours

  4. Subject global assessment of PRF110

    Subject global assessment which will be recorded at Hours 24, 48 and 72.

    Time frame: 72 hours

Other outcomes

  1. PRF110 plasma concentrations

    Samples will be collected at designated times up to 72hrs post drug application

    Time frame: 72 hours

07

Study locations

2 sites
  • The Chaim Sheba Medical Center
    Ramat Gan, 52621, Israel
    • Natan Bruck, Dr. · Contact+972-3-530-3030
  • Assaf Harofeh Medical Center
    Zerifin, 70300, Israel
    • Shai Efrati, Dr. · Contact+972-8-977-9393/5
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2016, a primary completion of Apr 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2016
First posted
May 27, 2016
Start
Aug 2016
Primary completionEst.
Apr 2017
CompletionEst.
Jun 2017
Last update
May 27, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02784327
Lead sponsor
PainReform LTD
Responsible party
Sponsor
First posted
May 27, 2016
Start date
Aug 2016
Primary completion
Apr 2017 (estimated)
Completion
Jun 2017 (estimated)
Last update
May 27, 2016

Study contacts

Sigal Aviel, Dr.
Contact
saviel@painreform.com
+972-9-9601911
Shai Efrati, Dr.
principal investigator · Assaf-Harofeh Medical Center
Natan Bruck, Dr.
principal investigator · The Chaim Sheba Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion